Publications by authors named "Fatima Miras"

Claim this Profile
A
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Birna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, Ferran Nadeu, Manja Meggendorfer, Fatima Miras

Leukemia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.
Aintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, Aina Oliver-Caldes, José J Perez

Am J Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.
Thomas Chatzikonstantinou, Lydia Scarfò, Eva Minga, Georgios Karakatsoulis, Dimitra Chamou, Fatima Miras

Hemasphere· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, Anargyros Kapetanakis, Christos Demosthenous

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
Thomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, Fatima Miras

EClinicalMedicine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Georgios Karakatsoulis, Manja Meggendorfer, Fatima Miras

Leukemia· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Georgios Karakatsoulis, Manja Meggendorfer, Fatima Miras

Leukemia· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic

J Hematol Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, Georgios Karakatsoulis, David Allsup

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Lindsey E Roeker, Toby A Eyre, Meghan C Thompson, Nicole Lamanna, Alexander R Coltoff, Fatima Miras

Blood· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Joaquin Martinez-Lopez, Rafael Alonso, Sandy W Wong, Rafael Rios, Nina Shah, Fatima Miras

J Hematol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Ana Muntañola, Guillermo Villacampa, José Ángel Hernández-Rivas, Rosalía Alonso, Fátima Mirás

Exp Hematol Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta

Leukemia· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Anthony R Mato, Lindsey E Roeker, Nicole Lamanna, John N Allan, Lori Leslie, Fatima Miras

Blood· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Yair Herishanu, Adir Shaulov, Riva Fineman, Sandra Bašić-Kinda, Ariel Aviv

Am J Hematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis